LHRH agonists reduce risk of recurrence and delay death
16 October 2009
| by Amy Corderoy
The inclusion of an LHRH agonist as adjuvant therapy for premenopausal women with endocrine sensitive early breast cancer is likely to lead to a reduction in the risk of a recurrence and a delay in death, a Cochrane review finds....
Want to read complete article? Please Sign in or Register.